About VBS
Vectus Biosystems Limited (VBS) is developing treatments for fibrosis, including for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Funds from the IPO and from two subsequent fundraisings were used predominantly to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure.
Find out what a historical investment in Vectus Biosystems would be worth today using our VBS stock calculator.
Market Capitalisation
$6.53M
Price-earnings ratio
3.74
Dividend yield
-
High today
$0.11
Low today
$0.11
Open price
$0.11
52-week high
$0.46
52-week low
$0.09
Ready to start your investing journey with Stake?
Open an accountAnnouncements
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in VBS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in VBS on Stake
- Buy VBS from A$3 brokerage
- Invest in 2,500+ Aussie stocks and ETFs
- CHESS-sponsored ASX trades
Stock shown for demonstrative purposes only. A$3 brokerage up to A$30,000.
VBS related stocks